The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new ...

The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable ...

Travere Therapeutics was first featured on our site on August 14, 2024, when the stock was trading at $8.91. At the time, our ...

Risicowaarschuwing: Handelen in financiële instrumenten en/of cryptovaluta gaat gepaard met een hoog risico, zoals de kans ...

The FDA’s Office of Prescription Drug Promotion sent Travere Therapeutics a letter over its advertising for Filspari, a drug that’s approved to slow kidney function decline in people with primary IgA ...

Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Travere Therapeutics, Inc.: Cours de bourse, graphiques, cotations, conseils boursiers, données financières, analyses et actualités en temps réel Action Travere Therapeutics, Inc. | TVTX | US89422G107 ...

For 2Q26, Nomura Smid Cap Core Fund Institutional Class shares performed in-line with the Fund's benchmark, the Russell 2500 ...

云顶新耀在心血管领域，拿下了一张关键“王牌”。 9月3日，云顶新耀宣布，中国国家药品监督管理局（NMPA）已批准星必妥®（艾曲帕米鼻喷雾剂）的新药上市许可申请（NDA），用于治疗成人阵发性室上性心动过速（PSVT）急性症状发作，转复为窦性心律。 这是云顶新耀在心血管疾病领域首个获批的创新药物，更重要的是，星必妥®所切入的并非传统院内治疗场景，而是PSVT急性发作时患者院外的应急自救治疗需求。 对于 ...

除安斯泰来外，公司曾将BTK抑制剂XNW1011的肾病领域全球权益授权给云顶新耀（首付款1200万美元、里程碑最高5.49亿美元，信诺维与中国抗体按2:1分成），将自免适应症权益转让给中国抗体（技术转让费合计1.4亿元人民币）； ...

上升曲线非常清晰作者：西北哽过去几年，创新药行业有一个很现实的问题：一款创新药获批上市，并不意味着企业就能真正跑起来。从研发到商业化，中间隔着多个环节。很多创新药企能够做出产品，却很难把产品变成持续增长的商业能力。但云顶新耀正在走出一条不太一样的路径 ...